Iron Chelation Therapy in Beta Thalassaemia Major

2007 ◽  
pp. 145-152
Author(s):  
Beatrix Wonke
Keyword(s):  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Thalassaemia Major ◽  
Beta Thalassaemia

Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major

2006 ◽  
Vol 134 (4) ◽  
pp. 438-444 ◽  
Author(s):  
Kalistheni Farmaki ◽  
Nicholas Angelopoulos ◽  
George Anagnostopoulos ◽  
Efstathios Gotsis ◽  
Grigorios Rombopoulos ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Thalassaemia Major

Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy

2014 ◽  
Vol 36 (1) ◽  
pp. 22-27 ◽  
Author(s):  
Rajni Sharma ◽  
Anju Seth ◽  
Jagdish Chandra ◽  
Suraj Gohain ◽  
Seema Kapoor ◽  
...  
Keyword(s):  
Chelation Therapy ◽  
Iron Chelation ◽  
Oral Iron ◽  
Iron Chelation Therapy ◽  
Thalassaemia Major

Marrow proliferation as a cause of hearing loss in beta-thalassaemia major

2007 ◽  
Vol 122 (11) ◽  
pp. 1253-1256 ◽  
Author(s):  
D Thio ◽  
V Prasad ◽  
P Anslow ◽  
P Lennox
Keyword(s):  
Hearing Loss ◽  
Chelation Therapy ◽  
Disease Process ◽  
Iron Chelation ◽  
Ossicular Chain ◽  
Thalassaemia Major ◽  
Beta Thalassaemia ◽  
Marrow Expansion ◽  
Desferrioxamine Therapy ◽  
New Onset

AbstractObjective:The aim of this report was to highlight the fact that hearing loss in thalassaemia patients can be related to marrow expansion affecting the ossicles, resulting in a conductive loss.Case report:A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy. Otoxicity was assumed, but the deficit was later found to be of a conductive nature, due to marrow proliferation within the ossicular chain as a consequence of the disease process – a phenomenon previously unreported in the literature.Conclusion:It is important to elucidate the precise nature of new onset hearing loss in patients receiving iron chelation therapy, in order to avoid unnecessary cessation of much needed medication, on the assumption of ototoxicity.

Cardiac iron measurement and iron chelation therapy in patients with β thalassaemia major: experience from Taiwan

2013 ◽  
Vol 23 (2) ◽  
pp. 100-107 ◽  
Author(s):  
M. -Y. Lu ◽  
S. S. F. Peng ◽  
H. -H. Chang ◽  
Y. -L. Yang ◽  
C. -A. Chen ◽  
...  
Keyword(s):  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Thalassaemia Major ◽  
Cardiac Iron

Iron Chelation Therapy in CAPD: A New and Effective Treatment of Iron Overload Disease in Esrd Patients

1983 ◽  
Vol 3 (2) ◽  
pp. 99-101 ◽  
Author(s):  
Glen H Stanbaugh ◽  
A. W, Holmes Diane Gillit ◽  
George W. Reichel ◽  
Mark Stranz
Keyword(s):  
Peritoneal Dialysis ◽  
Iron Overload ◽  
End Stage Renal Disease ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Peritoneal Dialysate ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

A patient with end-stage renal disease on CAPD, and with massive iron overload is reported. This patient had evidence of myocardial and hepatic damage probably as a result of iron overload. Treatment with desferoxamine resulted in removal of iron in the peritoneal dialysate. On the basis of preliminary studies in this patient it would appear that removal of iron by peritoneal dialysis in conjunction with chelation therapy is safe and effective. This finding should have wide-ranging signficance for patients with ESRD.

Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

Hemoglobin ◽  
2009 ◽  
Vol 33 (sup1) ◽  
pp. S58-S69 ◽  
Author(s):  
Maria D. Cappellini ◽  
Khaled M. Musallam ◽  
Ali T. Taher
Keyword(s):  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy
Sign in / Sign up

Export Citation Format

Share Document